Citizens Financial Group Inc. RI Raises Position in The Cooper Companies, Inc. $COO

Citizens Financial Group Inc. RI lifted its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 14.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,989 shares of the medical device company’s stock after purchasing an additional 876 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in Cooper Companies were worth $497,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of COO. Sustainable Growth Advisers LP bought a new stake in Cooper Companies in the second quarter worth $240,881,000. Goldman Sachs Group Inc. raised its stake in shares of Cooper Companies by 17.0% in the first quarter. Goldman Sachs Group Inc. now owns 4,734,327 shares of the medical device company’s stock valued at $399,340,000 after acquiring an additional 686,751 shares during the period. Millennium Management LLC raised its stake in shares of Cooper Companies by 36.0% in the first quarter. Millennium Management LLC now owns 2,577,416 shares of the medical device company’s stock valued at $217,405,000 after acquiring an additional 682,166 shares during the period. Nuveen LLC bought a new stake in shares of Cooper Companies in the 1st quarter worth about $55,367,000. Finally, Alecta Tjanstepension Omsesidigt boosted its stake in shares of Cooper Companies by 60.7% during the 2nd quarter. Alecta Tjanstepension Omsesidigt now owns 1,349,500 shares of the medical device company’s stock worth $96,030,000 after purchasing an additional 509,800 shares during the period. Institutional investors own 24.39% of the company’s stock.

Insider Activity at Cooper Companies

In other Cooper Companies news, COO Gerard H. Warner III acquired 1,450 shares of Cooper Companies stock in a transaction that occurred on Friday, September 5th. The stock was bought at an average price of $69.23 per share, with a total value of $100,383.50. Following the completion of the purchase, the chief operating officer directly owned 18,319 shares of the company’s stock, valued at approximately $1,268,224.37. This represents a 8.60% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brian G. Andrews bought 1,525 shares of the stock in a transaction on Tuesday, September 2nd. The shares were bought at an average price of $65.68 per share, with a total value of $100,162.00. Following the acquisition, the executive vice president owned 22,191 shares of the company’s stock, valued at $1,457,504.88. This trade represents a 7.38% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 17,975 shares of company stock valued at $1,216,346 over the last quarter. 1.98% of the stock is owned by insiders.

Cooper Companies Stock Performance

COO stock opened at $72.20 on Wednesday. The Cooper Companies, Inc. has a 1-year low of $61.78 and a 1-year high of $106.63. The business has a 50-day moving average price of $69.83 and a 200 day moving average price of $72.09. The company has a market capitalization of $14.35 billion, a P/E ratio of 35.57, a PEG ratio of 1.83 and a beta of 1.02. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.12 and a quick ratio of 1.24.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.03. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. The company had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the prior year, the business earned $0.96 EPS. The firm’s quarterly revenue was up 5.7% on a year-over-year basis. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, equities research analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies announced that its Board of Directors has authorized a share repurchase plan on Wednesday, September 17th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical device company to buy up to 15.4% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

A number of analysts recently weighed in on COO shares. Robert W. Baird reduced their price objective on shares of Cooper Companies from $97.00 to $85.00 and set an “outperform” rating on the stock in a research report on Thursday, August 28th. BNP Paribas Exane upgraded Cooper Companies from a “neutral” rating to an “outperform” rating and set a $92.00 price target on the stock in a report on Tuesday, July 22nd. Barclays initiated coverage on Cooper Companies in a research note on Monday, October 13th. They set an “overweight” rating and a $85.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $94.00 price objective on shares of Cooper Companies in a research report on Thursday, August 28th. Finally, Morgan Stanley set a $76.00 target price on Cooper Companies and gave the stock an “equal weight” rating in a research report on Thursday, August 28th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $84.77.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.